Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.53 |
| ▸ | F11 | P03951 | 3/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290411 | 0.85 | LPL (0.53) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL21370131 | 0.85 | LPL (0.53) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL418767 | 0.85 | LPL (0.56) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL15615747 | 0.84 | LPL (0.49) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL24871312 | 0.84 | LPL (0.51) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL23577225 | 0.84 | LPL (0.51) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL12630073 | 0.83 | LPL (0.55) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL17457 | 0.82 | NR1H2 (0.50) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL25626118 | 0.82 | LPL (0.50) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL13507405 | 0.82 | LPL (0.50) | LPLLIPGF11F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230371363-A1 | COMPOUNDS THAT CAN BE USED FOR STRUCTURING FUNCTIONAL LAYERS OF ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | US | disclosed |
| EP-4222792-A1 | COMPOUNDS THAT CAN BE USED FOR STRUCTURING FUNCTIONAL LAYERS OF ORGANIC ELECTROLUMINESCENT DEVICES | Merck Patent GmbH (DE) | 2023-08-09 | — | — | EP | disclosed |
| CN-116508417-A | Compounds useful for structuring functional layers of organic electroluminescent devices | 默克专利有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022069421-A1 | COMPOUNDS THAT CAN BE USED FOR STRUCTURING FUNCTIONAL LAYERS OF ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2022-04-07 | — | — | WO | disclosed |
| CN-107922437-B | Bridged piperidine derivatives | 豪夫迈·罗氏有限公司 | 2021-12-10 | — | — | CN | disclosed |
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180237432-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3347363-A1 | BRIDGED PIPERIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-07-18 | — | — | EP | disclosed |
| CN-107922437-A | Bridging piperidine derivative | 豪夫迈·罗氏有限公司 | 2018-04-17 | — | — | CN | disclosed |
| WO-2017042114-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017042114-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237432-A1 | BRIDGED PIPERIDINE DERIVATIVES | HPGDS, APP, PSEN1 | LPL 1020/4885LIPG 296/4885F11 3631/4885 |
| US-10604517-B2 | Bridged piperidine derivatives | HPGDS, APP, PSEN1 | LPL 1020/4885LIPG 296/4885F11 3631/4885 |
| US-20230371363-A1 | COMPOUNDS THAT CAN BE USED FOR STRUCTURING FUNCTIONAL LAYERS OF ORGANIC ELECTROLUMINESCENT DEVICES | EPCAM, SELE, CTCF | LPL 2596/4885LIPG 1823/4885F11 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.